The European Medicines Agency said it has received a request from Merck to authorise its coronavirus antiviral, the first pill shown to treat COVID-19.
US advisors to meet this month to vote on authorisation
Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide
The pharmaceutical company Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the first pill that has been shown to treat the disease
If cleared by the Food and Drug Administration a decision that could come in a matter of weeks it would be the first pill shown to treat Covid
Potentially, the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people
Drug cuts hospitalisation, deaths by 50%, shows an analysis of a late-stage trial
Merck & Co said Friday that its experimental COVID-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorize its use. If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorised in the US require an IV or injection. Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalisation and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease. Among patients taking molnupiravir, 7.3 per cent were either hospitalised or died at the end of 30 .
Merck announced a donation of Rs 1.7 crore over two years to the IIT, Bombay to support the development of clinical tests for COVID-19 disease severity assessment
Science and technology firm Merck on Tuesday announced a support of 2 million euros (Rs 17.85 crore) for India to help the country fight against Covid-19
US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine.""This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he addedBiden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May."This country will have enough vaccines supply for ..
President Joe Biden is expected to make the announcement on Tuesday, the report said
The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday
Frazier, 66, will remain with the drugmaker as executive chairman for a transition period to be determined by the board.
That is above the average of 404 drug price increases in the first three days of January over the past five years
The spread in the yield curve has gainedabout 20 basis points since leaving negative territory, a recession indicator, in early September
Out of the 77.80% paid-up equity share capital, 51.80% was held by current promoters and up to 26% by public shareholders: Merck
The stock locked in the lower circuit for the second straight day, down 5% at Rs 3,064 on the BSE.
Thus far in the calendar year 2018, the stock of this pharmaceutical company has zoomed 107% from Rs 1,289, as compared to 4% rise in the S&P BSE Sensex.
The stock hit new high of Rs 2,369, rallied 57% from Rs 1,510 since April 19, after P&G Overseas India makes mandatory open offer to acquire 26% stake in the company at price of Rs 1,500.36 per share.